GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score
暂无分享,去创建一个
G. Gores | J. Marrero | Ziding Feng | Ning Zhang | W. Harmsen | K. Reddy | N. Giama | C. Moser | L. Roberts | Ju Dong Yang | S. Srivastava | M. Schwartz | K. Mara | D. Harnois | A. Algeciras-Schimnich | M. Nguyen | A. Befeler | J. Rinaudo | Jianliang Dai | Hiroyuki Yamada | Loretta K. Allotey | J. Theobald | B. Addissie | S. Lavu | Nicha Wongjarupong | K. Miyabe | H. A. Ali | Jessica L Cvinar | H. Ali | Fatima Hassan | Melissa M. Ward | J. Yang | J. D. Yang
[1] W. Kim,et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis , 2018, Hepatology.
[2] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[3] M. Kudo,et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.
[4] Alan D. Lopez,et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.
[5] Jasmin A. Tiro,et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis , 2017, Hepatology.
[6] G. Gores,et al. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[7] J. Marrero,et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis , 2017, Alimentary pharmacology & therapeutics.
[8] C. Lu,et al. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis , 2016, The American Journal of Gastroenterology.
[9] M. Manns,et al. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] Ahmedin Jemal,et al. Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.
[11] M. Rizzetto,et al. Highly sensitive alpha‐fetoprotein, Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein and des‐gamma‐carboxyprothrombin for hepatocellular carcinoma detection , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.
[12] Y. Takikawa,et al. Alpha‐fetoprotein: A biomarker for the recruitment of progenitor cells in the liver in patients with acute liver injury or failure , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[13] C. Lu,et al. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis , 2015, The American Journal of Gastroenterology.
[14] L. Roberts,et al. Update on biomarkers of hepatocellular carcinoma. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] Amit G. Singal,et al. Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis , 2014, PLoS medicine.
[16] H. Reeves,et al. The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[17] J. Marrero,et al. Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[18] T. Therneau,et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[19] Cher Heng Tan,et al. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review , 2011, International journal of hepatology.
[20] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[21] Lewis R. Roberts,et al. Hepatocellular carcinoma: a global view , 2010, Nature Reviews Gastroenterology &Hepatology.
[22] William M. Lee,et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.
[23] J. Marrero,et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. , 2009, Gastroenterology.
[24] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[25] S. Porru,et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. , 2002, American journal of epidemiology.
[26] B. McMahon,et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study , 2000, Hepatology.
[27] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[28] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[29] H. El‐Serag,et al. Phase 3 biomarker study for HCC surveillance using AFP, AFP L-3 and DCP. A prospective collection with retrospective blinded evaluation , 2017 .
[30] M. Sherman,et al. A randomized controlled trial of US vs US + biomarkers for the diagnosis of hepatocellular carcinoma: an interim report , 2017 .
[31] N. Chavez-Tapia,et al. Clinical practice guidelines: Management of Hepatocellular Carcinoma , 2014 .
[32] T. Therneau,et al. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. , 2012, Mayo Clinic proceedings.
[33] W. Kim,et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[34] T. Therneau,et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[35] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.